On July 25, 2025, Tharimmune, Inc. announced a securities purchase agreement for a private placement, issuing 641,190 shares of common stock and warrants, with expected gross proceeds of $1,225,003 to fund clinical development and working capital. The closing of this placement occurred on July 31, 2025.